GlassScriptPhysician profile
Peter Alexander Beale
NPI 1952713075
$1,124.37
in general payments reported to CMS, 2019-2025
20 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $363 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.38 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $135.65 | 2024-2025 | |
| Genzyme Corporation | $117.66 | 2024-2025 | |
| Gilead Sciences, INC. | $96.59 | 2024-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $95.95 | 2024-2025 | Xpovio |
| Abbvie INC. | $92.59 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $65.69 | 2025 | |
| Genmab U.S., INC. | $65.53 | 2025 | Epkinly |
| Incyte Corporation | $65.38 | 2024-2025 | Jakafi, Niktimvo |
| Exelixis INC. | $64.22 | 2024-2025 | Cabometyx |
| Sobi, INC | $54.69 | 2024-2025 | |
| Beone Medicines USA, INC. | $44.43 | 2025 | Brukinsa, Tevimbra |
| Celgene Corporation | $37.43 | 2025 | Opdivo |
| Daiichi Sankyo INC. | $27.46 | 2025 | Enhertu |
| Geron Corporation | $26.36 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $25.96 | 2025 | Besremi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.48 | 2025 | |
| Adc Therapeutics America, INC. | $23.95 | 2024 | |
| Coherus Oncology, INC. | $22.69 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.85 | 2024 | |
| Merck Sharp & Dohme LLC | $18.81 | 2025 | Keytruda Qlex, Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Beale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.